Founder of AUM Biosciencesand Chairman of AUM’s Board of Directors.
Extensive experience in structuring and managing global deals worth over US$4 billion in drug development with major pharmaceuticals, and biotech companies.
Previously held senior business development and management roles at IQVIA, EPS International and ICONand many more reputed global enterprises
Achieved 145M USD PE deal with a major pharmaceutical company that resulted in achieving POC for 3 major oncology drugs currently on the market with peak sales of over 4B USD combined along with other founders
Within 12 months of inception, successfully lead AUM Bioscience transition from a pre-clinical to a clinical stagecompany and developed a portfolio of transformative cancer medicines
Awarded the2019 Asia-Pacific Biotech Entrepreneurial Company of The Year by Frost and Sullivan.
Nominated as aYoung Global Leader by the World Economic Forum for Class of 2021.
Key Opinion Leader to Korean Health Industry Development Institute
Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer.